95 related articles for article (PubMed ID: 28133186)
61. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
[TBL] [Abstract][Full Text] [Related]
62. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
63. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
[TBL] [Abstract][Full Text] [Related]
64. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
Iwasa S; Nakajima TE; Nakamura K; Takashima A; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Gastric Cancer; 2012 Jan; 15(1):21-6. PubMed ID: 21573919
[TBL] [Abstract][Full Text] [Related]
65. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination.
Imazawa M; Kojima T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yasui H; Yamazaki K; Taku K
Gastric Cancer; 2009; 12(3):153-7. PubMed ID: 19890695
[TBL] [Abstract][Full Text] [Related]
66. Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients.
Di Bartolomeo M; Bajetta E; Somma L; Carnaghi C; Bandieri E; Del Vecchio M; Gallo Stampino C; Buzzoni R
Oncology; 1996; 53(1):54-7. PubMed ID: 8570132
[TBL] [Abstract][Full Text] [Related]
67. [A Case of Effective Palliative Care with CART for Refractory Ascites Associated with Cancerous Peritonitis of Gastric Cancer].
Kawada J; Nishino M; Hata T; Ogino T; Hoshino H; Okano M; Nagai K; Kim Y; Okuyama M; Tsujinaka T
Gan To Kagaku Ryoho; 2018 Apr; 45(4):700-702. PubMed ID: 29650840
[TBL] [Abstract][Full Text] [Related]
68. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
[TBL] [Abstract][Full Text] [Related]
69. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.
Imamoto H; Oba K; Sakamoto J; Iishi H; Narahara H; Yumiba T; Morimoto T; Nakamura M; Oriuchi N; Kakutani C; Morita S; Shiozaki H
Gastric Cancer; 2011 Mar; 14(1):81-90. PubMed ID: 21327925
[TBL] [Abstract][Full Text] [Related]
70. WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.
Masuishi T; Nakajima TE; Yamazaki K; Hironaka S; Kudo C; Yoshimura K; Muro K
Future Oncol; 2020 Jul; 16(20):1417-1424. PubMed ID: 32466683
[TBL] [Abstract][Full Text] [Related]
71. A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice.
Watson SA; Michaeli D; Grimes S; Morris TM; Varro A; Clarke PA; Smith AM; Justin TA; Hardcastle JD
Int J Cancer; 1999 Apr; 81(2):248-54. PubMed ID: 10188727
[TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.
Kobayashi M; Sakamoto J; Namikawa T; Okamoto K; Okabayashi T; Ichikawa K; Araki K
World J Gastroenterol; 2006 Mar; 12(9):1412-5. PubMed ID: 16552811
[TBL] [Abstract][Full Text] [Related]
73. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake.
Osumi H; Takahari D; Chin K; Ogura M; Ichimura T; Wakatsuki T; Suzuki T; Ota Y; Nakayama I; Ooki A; Suenaga M; Shinozaki E; Yamaguchi K
Onco Targets Ther; 2018; 11():8301-8307. PubMed ID: 30538499
[TBL] [Abstract][Full Text] [Related]
74. A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer.
Sakamoto J; Morita S; Yumiba T; Narahara H; Kinoshita K; Nakane Y; Imamoto H; Shiozaki H;
Jpn J Clin Oncol; 2003 May; 33(5):238-40. PubMed ID: 12865468
[TBL] [Abstract][Full Text] [Related]
75. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy.
Nagata Y; Kato K; Miyamoto T; Hirano H; Shoji H; Iwasa S; Honma Y; Takashima A; Hamaguchi T; Matsushita H; Nagashima K; Saruta M; Boku N
Support Care Cancer; 2020 Dec; 28(12):5861-5869. PubMed ID: 32253601
[TBL] [Abstract][Full Text] [Related]
76. Chemotherapy in gastric cancer: a never ending saga.
Roth AD
Ann Oncol; 2003 Feb; 14(2):175-7. PubMed ID: 12562640
[No Abstract] [Full Text] [Related]
77. Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites.
Hamamoto Y; Piao Y; Makiyama A
Gastric Cancer; 2020 May; 23(3):363-372. PubMed ID: 32236760
[TBL] [Abstract][Full Text] [Related]
78. Intensifying supportive care is associated with improved survival in gastric cancer patients with malignant ascites.
Karalis JD; Ju MR; Feig R; Estrella R; Pettigrew MF; Alterio RE; Abreu AA; Farah E; Sawas T; Sanford NN; Sanjeevaiah A; Hammer STG; Porembka MR; Wang SC
J Surg Oncol; 2024 Mar; 129(4):718-727. PubMed ID: 38063245
[TBL] [Abstract][Full Text] [Related]
79. PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
HART GD
Can Med Assoc J; 1964 May; 90(22):1265-8. PubMed ID: 14158958
[TBL] [Abstract][Full Text] [Related]
80. Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF.
Xie H; Lu Q; Wang H; Zhu X; Guan Z
Oncol Lett; 2019 Jan; 17(1):933-936. PubMed ID: 30655850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
